Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dissecting the shared genetic landscape of anxiety, depression, and schizophrenia.

Journal of translational medicine - 18 Apr 2024

Tao Yiming, Zhao Rui, Yang Bin, Han Jie, Li Yongsheng

Abstract excerpt

BACKGROUND: Numerous studies highlight the genetic underpinnings of mental disorders comorbidity, particularly in anxiety, depression, and schizophrenia. However, their shared genetic loci are not well understood. Our study employs Mendelian randomization (MR) and colocalization analyses, alongside multi-omics data, to uncover potential genetic targets for these conditions, thereby informing therapeutic and drug...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, CD
Share to Anxiety
Share to Anxiety Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Butyrophilins

Share to Depression

Share to Molecular Docking Simulation

Share to Proteasome Endopeptidase Complex

Share to Schizophrenia

Source

Open in PubMed Open full text

Identifiers

PMID: 38637810
DOI: 10.1186/s12967-024-05153-3
PMCID: PMC11025255

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dissecting the shared genetic landscape of anxiety, depression, and schizophrenia.PMID 38637810Read ↗

Mendelian Randomization Using the Druggable Genome Reveals Genetically Supported Drug Targets for Psychiatric Disorders.Semantic proximity Read ↗

Genome-wide Mendelian randomization identifies actionable novel drug targets for psychiatric disorders.Semantic proximity Read ↗

Identifying circulating protein targets for common factors underlying schizophrenia, depression, and bipolar disorderSemantic proximity Read ↗

Genetic analyses point to alterations in immune-related pathways underpinning the association between psychiatric disorders and COVID-19Semantic proximity Read ↗

Novel loci and potential mechanisms of major depressive disorder, bipolar disorder, and schizophrenia.Semantic proximity Read ↗

Convergent proteogenomic evidence prioritises five causal proteins and new drug targets for major psychiatric disordersSemantic proximity Read ↗

Identification of Shared Genetic Variants and Haplotypes Associated With Schizophrenia and Depression.Semantic proximity Read ↗

Genetic interactions between bioactive ingredients in traditional Chinese medicine and major depressive disorder, bipolar disorder, and schizophrenia.Semantic proximity Read ↗

Identification of 64 new risk loci for major depression, refinement of the genetic architecture and risk prediction of recurrence and comorbiditiesSemantic proximity Read ↗

Genetic analyses point to alterations in immune-related pathways underpinning the association between psychiatric disorders and COVID-19.Semantic proximity Read ↗

Transcriptomic integration nominates FOXN2 as a candidate schizophrenia risk gene.Semantic proximity Read ↗

Bayesian colocalization of psychiatric disorder GWAS signals with molecular quantitative trait loci highlights histone involvement and neuroimmune dysregulation in pathogenesis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.